Back to Search
Start Over
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
- Source :
- Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021), Blood Cancer Journal
- Publication Year :
- 2021
- Publisher :
- Nature Publishing Group, 2021.
-
Abstract
- Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody–drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit–risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf.
- Subjects :
- medicine.medical_specialty
Visual acuity
genetic structures
Eye care
Antibodies, Monoclonal, Humanized
Article
Corneal Diseases
Cornea
Antineoplastic Agents, Immunological
Superficial punctate keratopathy
Internal medicine
Medicine
Humans
In patient
Hematologist
Intensive care medicine
RC254-282
Cancer
Patient Care Team
Haematological cancer
Hematology
medicine.diagnostic_test
business.industry
Disease Management
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Refractory Multiple Myeloma
eye diseases
Oncology
Eye examination
sense organs
medicine.symptom
Neoplasm Recurrence, Local
business
Multiple Myeloma
Subjects
Details
- Language :
- English
- ISSN :
- 20445385 and 03525678
- Volume :
- 11
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Blood Cancer Journal
- Accession number :
- edsair.doi.dedup.....daa8f75c6ed9c4ec8ae621142d8e7fd9